These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 31028563)

  • 81. Hypertension and sympathetic hyperactivity induced in rats by high-fat or glucose diets.
    Kaufman LN; Peterson MM; Smith SM
    Am J Physiol; 1991 Jan; 260(1 Pt 1):E95-100. PubMed ID: 1987797
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Melanocortin-4 receptor mediates chronic cardiovascular and metabolic actions of leptin.
    Tallam LS; da Silva AA; Hall JE
    Hypertension; 2006 Jul; 48(1):58-64. PubMed ID: 16754792
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Impact of sex and age on metabolism, sympathetic activity, and hypertension.
    Yoo JK; Fu Q
    FASEB J; 2020 Sep; 34(9):11337-11346. PubMed ID: 32779294
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Overweight and hypertension : a 2-way street?
    Julius S; Valentini M; Palatini P
    Hypertension; 2000 Mar; 35(3):807-13. PubMed ID: 10720599
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Sex differences in sympathetic activity in obesity and its related hypertension.
    Fu Q
    Ann N Y Acad Sci; 2019 Oct; 1454(1):31-41. PubMed ID: 31087350
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Enhanced adipose afferent reflex contributes to sympathetic activation in diet-induced obesity hypertension.
    Xiong XQ; Chen WW; Han Y; Zhou YB; Zhang F; Gao XY; Zhu GQ
    Hypertension; 2012 Nov; 60(5):1280-6. PubMed ID: 23033372
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The role of the sympathetic nervous system in linking obesity with hypertension in white versus black Americans.
    Eslami P; Tuck M
    Curr Hypertens Rep; 2003 Jun; 5(3):269-72. PubMed ID: 12724061
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Melanocortin-4 receptor agonists for the treatment of obesity.
    Emmerson PJ; Fisher MJ; Yan LZ; Mayer JP
    Curr Top Med Chem; 2007; 7(11):1121-30. PubMed ID: 17584132
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Sex differences in weight gain, blood pressure control, and responses to melanocortin-4 receptor antagonism in offspring from lean and obese parents.
    do Carmo JM; Dai X; Aitken N; Larson KM; Omoto ACM; Gulke RR; Wang Z; Li X; Mouton AJ; Hall JE; da Silva AA
    Am J Physiol Regul Integr Comp Physiol; 2023 Oct; 325(4):R401-R410. PubMed ID: 37519251
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Improving obesity and blood pressure.
    Tanaka M
    Hypertens Res; 2020 Feb; 43(2):79-89. PubMed ID: 31649313
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Central mineralocorticoid receptors, sympathetic activity, and hypertension.
    McManus F; MacKenzie SM; Freel EM
    Curr Hypertens Rep; 2009 Jun; 11(3):224-30. PubMed ID: 19442333
    [TBL] [Abstract][Full Text] [Related]  

  • 92. A sympathetic view of human obesity.
    Lambert EA; Straznicky NE; Lambert GW
    Clin Auton Res; 2013 Feb; 23(1):9-14. PubMed ID: 22717677
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Melanocortin-4 receptor gene polymorphism and the level of physical activity in men (HALS Study).
    Jóźków P; Słowińska-Lisowska M; Łaczmański Ł; Jakubiec D; Mędraś M
    Endocrine; 2011 Feb; 39(1):62-8. PubMed ID: 21046283
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Neuroimmune communication in hypertension and obesity: a new therapeutic angle?
    de Kloet AD; Krause EG; Shi PD; Zubcevic J; Raizada MK; Sumners C
    Pharmacol Ther; 2013 Jun; 138(3):428-40. PubMed ID: 23458610
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications.
    Valensi P
    Cardiovasc Diabetol; 2021 Aug; 20(1):170. PubMed ID: 34412646
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Sympathetic nervous activation in obesity and the metabolic syndrome--causes, consequences and therapeutic implications.
    Lambert GW; Straznicky NE; Lambert EA; Dixon JB; Schlaich MP
    Pharmacol Ther; 2010 May; 126(2):159-72. PubMed ID: 20171982
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Central nervous system dysfunction in obesity-induced hypertension.
    Head GA; Lim K; Barzel B; Burke SL; Davern PJ
    Curr Hypertens Rep; 2014 Sep; 16(9):466. PubMed ID: 25090962
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A sympathetic view of the sympathetic nervous system and human blood pressure regulation.
    Joyner MJ; Charkoudian N; Wallin BG
    Exp Physiol; 2008 Jun; 93(6):715-24. PubMed ID: 18326553
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Collateral damage: cardiovascular consequences of chronic sympathetic activation with human aging.
    Seals DR; Dinenno FA
    Am J Physiol Heart Circ Physiol; 2004 Nov; 287(5):H1895-905. PubMed ID: 15475526
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Vascular effects of deletion of melanocortin-4 receptors in rats.
    Stepp DW; Osakwe CC; Belin de Chantemele EJ; Mintz JD
    Physiol Rep; 2013 Nov; 1(6):e00146. PubMed ID: 24400148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.